Donald McGovern, Jr. Biography and Net Worth

Director of 180 Life Sciences

Donald A. McGovern, Jr is the former Vice Chairman, Global Assurance, of PricewaterhouseCoopers LLP (PwC). Through decades of leadership at PwC and board experience, Don brings wide-ranging operational, financial, accounting and audit and public company experience. He currently serves on the board of Cars.com. Don joined the board of Cars.com in May 2017 upon the spinout of Cars.com from Tegna creating a new public company listed on the NYSE. Don is chair of the Audit Committee and a member of the Compensation Committee at Cars.com, and a designated financial expert under SEC regulations. His past public board experience has been with CRH, plc. Don served two three-year terms (2013-2019) on the Board of CRH. During his tenure, he was Senior Independent Director, chair of the Remuneration Committee, a member of the Nomination Committee and of the Audit Committee and a designated financial expert under US SEC and UK FRC regulations.

How do I contact Donald A. McGovern, Jr.?: The corporate mailing address for Mr. McGovern, Jr. and other 180 Life Sciences executives is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. 180 Life Sciences can also be reached via phone at (650) 507-0669 and via email at [email protected]. Learn More on Donald A. McGovern, Jr.'s contact information.
Has Donald A. McGovern, Jr. been buying or selling shares of 180 Life Sciences?: Donald A. McGovern, Jr. has not been actively trading shares of 180 Life Sciences in the last ninety days. Learn More on Donald A. McGovern, Jr.'s trading history.
Who are 180 Life Sciences' active insiders?: 180 Life Sciences' insider roster includes Donald McGovern, Jr. (Director), Ozan Pamir (CFO), Quan Vu (COO), and James Woody (CEO). Learn More on 180 Life Sciences' active insiders.

Donald A. McGovern, Jr. Insider Trading History at 180 Life Sciences

Donald A. McGovern, Jr. Buying and Selling Activity at 180 Life Sciences

180 Life Sciences Company Overview

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Today's Range

Now: $2.37

$2.25

$2.49

50 Day Range

MA: $2.66

$1.18

$6.47

2 Week Range

Now: $2.37

$1.16

$17.75

Volume

41,272 shs

Average Volume

795,365 shs

Market Capitalization

$2.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad

Click here and I’ll tell you everything you need to know.